Trials / Completed
CompletedNCT00494962
Study Comparing Lecozotan SR Two 5-mg Tablets Vs. Lecozotan SR One 10-mg Tablet in Healthy Subjects
An Open-Label, Single-Dose, Randomized, 2-Period, Crossover, Bioequivalence Study Between Two 5-mg Tablets and a New 10-mg Tablet Formulation of Lecozotan SR in Healthy Subjects.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
To determine the bioequivalence between two 5-mg tablets of lecozotan and the new 10-mg tablet of lecozotan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lecozotan SR |
Timeline
- Start date
- 2007-06-01
- Completion
- 2007-06-01
- First posted
- 2007-07-02
- Last updated
- 2007-12-05
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00494962. Inclusion in this directory is not an endorsement.